Compagnie Lombard Odier SCmA’s Denali Therapeutics DNLI Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$134K	–	623
2021 Q4	$134K	Hold	3,000	–	–	﹤0.01%	405
2021 Q3	$151K	Hold	3,000	–	–	﹤0.01%	385
2021 Q2	$235K	Hold	3,000	–	–	0.01%	322
2021 Q1	$171K	Sell	3,000 -1,000	-25%	-$66.9K	﹤0.01%	400
2020 Q4	$335K	Buy	+4,000	New	+$242K	0.01%	274

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Compagnie Lombard Odier SCmA's DNLI Position: Q1 2022 in Review

Compagnie Lombard Odier SCmA sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 3,000 shares — an estimated $134K sold.

Compagnie Lombard Odier SCmA first reported a position in DNLI in Q4 2020 and held it in 5 quarters. The position peaked at $335K in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

Compagnie Lombard Odier SCmA reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 3,000 Denali Therapeutics shares in Q1 2022, an estimated $134K.
Compagnie Lombard Odier SCmA first reported a position in Denali Therapeutics in Q4 2020 and held it in 5 quarters.
Compagnie Lombard Odier SCmA's Denali Therapeutics position peaked at $335K in Q4 2020.
190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2022, filed 27 Apr 2022.